Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615329 · ClinicalTrials.gov registry record
Huntsman Biopsy Study
A clinical trial, sponsored by State University of New York - Upstate Medical University.
- Terminated
- Registry status
- 142
- Enrollment target
NCT00615329: Clinical Trial study, sponsored by State University of New York - Upstate Medical University.
NCT00615329 is a clinical trial that was terminated before completion, run by State University of New York - Upstate Medical University. The registered enrollment target is 142 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00615329 was terminated before completion, sponsored by State University of New York - Upstate Medical University.
- TERMINATED
- Registry status
- 142 participants
- Enrollment target
Study Summary
Bone and soft tissue sarcomas are currently classified based upon light microscopy supplemented by immunohistochemistry, but within many if not all of these tumor histologic types, considerable heterogeneity exists not only in microscopic appearance but also in biologic behavior and prognosis. Progress in the directed treatment of these tumors, particularly the sarcomas, awaits characterization of the gene profiles for these tumors. Orthopedic oncology researchers at Huntsman Cancer Institute at the University of Utah are establishing a tumor bank for this purpose. The long term objectives of this work include: 1. creating tumor specific gene profiles to improve diagnostic accuracy 2. performing gene set validation for diagnostic predictive power 3. defining a discriminate gene list implicated in pathogenesis The tissue procured under this protocol at SUNY Upstate Medical University will be limited to excess soft tissue and bone tumor tissue from patients otherwise undergoing clinically indicated procedures for diagnosis or treatment under the care of the local principal investigator (PI) and will be forwarded to the central investigator, R. Lor Randall, MD at Huntsman Cancer Institute for use in the characterization of the gene profiles of these tumors.
Primary Outcome
sarcomas will be classified by researchers at Huntsman Institute
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2003-04 |
| Est. Completion | 2014-02 |
Why NCT00615329 stopped before completion
NCT00615329 is an observational study that tracks outcomes without assigning an intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00615329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00615329 about?
NCT00615329 is a clinical study titled "Huntsman Biopsy Study". Bone and soft tissue sarcomas are currently classified based upon light microscopy supplemented by immunohistochemistry, but within many if not all of these tumor histologic types, considerable heterogeneity exists not only in microscopic appearance but also in biologic behavior and prognosis. Progr...
What is the current status of trial NCT00615329?
This trial is currently terminated. The enrollment target is 142 participants. The study started on 2003-04. Estimated completion is 2014-02.
Who is sponsoring clinical trial NCT00615329?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia